Thomson Reuters

GENESEQ™ contains high quality, easy-to-understand annotated genetic sequences from worldwide patents — an essential tool for any organization that needs to know what’s happening in genomic-based life science discovery.

A pharmaceutical research company has been granted patents on a number of sequences. The R&D director must monitor competitors for patenting activity relating to similar sequences to ensure they're not infringing on the company's patent rights.

Searches in GENESEQ reveal infringements on patents that were filed previously by the company, raising the possibility of legal action to stop or prevent further activities by the competition and also to obtain compensation.

With GENESEQ, you can:

• Access more than 8.8 million patented sequences spanning 41 patent offices worldwide.
• Review detailed commercial summaries.
• Check sequences for existing patent obligations.
• Search for prior art before patenting.
• Interrogate potential patent infringements.
• Obtain data in advance of your competitors, with greater, earlier sequence coverage.
  

Why choose GENESEQ?

• More than 8.8 million patented sequences covering genetic discovery back to 1981. As many as 12,000 new records are added every two weeks, with each record annotated by highly-trained editorial staff.
• Search sequence information from around the world in a single database. 41 patent authorities are covered, including WO, US, EP, JP, DE, IN and CN. Foreign patents compose over 20% of the database — and English language titles are provided for each foreign patent.
• Patents can appear years before other sequence databases. With GENESEQ™ FASTAlert, you’ll be notified of new sequences within two weeks of patent publication date, putting you far ahead of the competition and ensuring that your IP professionals will not miss any potential infringements or competitor activities.